Rituximab Was The Iodine Marker Method And ~ (131) I-rituximab Was The Treatment Of Charge Lymphoma In Nude Mice Of Experimental Research

As a kind of treatment of tumors, radioimmunotherapy functions through the cytotoxic effect of radioactive nuclides that are combined to the tumor-specific or tumor-associated monoclonal antibodies. The monoclonal antibodies act primarily as carrier of radioactive nuclides as well as inducer of apoptosis, ADCC and CDC. On the other hand, the character of the target antigen is crucial to the efficacy. Therefore, chosing the specific monoclonal antibodies, target antigens and radioactive nuclides is critical to the effect of RIT.Rituximab is the human-mouse chimerism monoclonal anti-CD20 antibody produced through genetic engineering, of which the V region is of mouse origin and the rest is of human origin. CD20 presents an ideal selective target for B-cell lymphoma as it is expressed in pre-B cells, mature B cells and more than 90% of B-cell lymphoma. Rituximab binds to CD20 in B cells and induces cell lysis which will be enhanced if radioactive nuclides are combined with. As have been demonstrated in some in vitro experiments, Rituximab promotes the sensitivity of some drug-resistant lymph cells to chemotherapy drugs as well as induction of apoptosis of DHL-4 B lymph cells. In November of 1997, FDA approved Rituximab in clinical application as the first monoclonal-antibody drug.¹³¹I and ⁹⁰Y are the mostly used isotopes in RIT. ¹³¹I has the privilege of wide source, low price, easy labeling and detection while ⁹⁰Y is bound to combine with ¹¹¹In—ibritumomab tiuxetan in the imaging process. Therefore, we use ¹³¹I as the...